Journal of Clinical Oncology, 2008 ASCO Annual Meeting Proceedings (Post-Meeting Edition).
Vol 26, No 15S (May 20 Supplement), 2008: 15125
© 2008 American Society of Clinical Oncology

This Article Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Download to citation manager Rights & Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by El-Wahidy, G. F. Articles by El-Desoki, I. Search for Related Content PubMed Articles by El-Wahidy, G. F. Articles by El-Desoki, I.

Abstract

Epidermal growth factor expression affects clinical outcome in colorectal cancer

Faculty of Medicine, Mansoura, Egypt

15125

Background: To elucidate the level of ECFR expression in colorectal cancer and the impact of chemotherapy on survival according to this expression. Methods: 50 patients with CRC staged II and III (AJCC). Group I (20) cases with negative expression subjected to adjuvant chemotherapy Mayo clinic regimen. Group II with expressed EGFR (30) case sub classified to 2 subgroups (A) (17 cases) received Mayo Clinic regimen and subgroup (B) (13 cases) received intensive protocol (FOLFOX or FOLFIRI). Both groups were well balanced. Results: Table (1). Conclusions: 1- EGFR expressed in 60% of our cases 2- RFS was significantly higher in group I with -ve expression versus +ve expression. 3- OAS was higher in group I with -ve expression versus + ve expression but this increase didn't reach statistical significance. 4- In those subsets of patients with expressed EGFR the mean value of survival was better in the group received intensive chemotherapy than those received conventional protocol (Mayo regimen) although the difference didn't reach statistical significance.

No significant financial relationships to disclose.